MedTrace Logo

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

NCT04699968 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-06-07

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without famitinib in patients with advanced or metastatic NSCLC

Conditions

  • Non-Small-Cell Lung Cancer

Interventions

DRUG

SHR-1701，Famitinib

SHR -1701, Intravenous ；Famitinib, oral

DRUG

SHR-1701

SHR -1701, Intravenous

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-15
Primary Completion
2021-11-15
Completion
2021-11-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04699968 on ClinicalTrials.gov